Abstracts tagged "Disease Activity"

Abstract Number: 0985 • ACR Convergence 2022
S100 Serum Protein Expression Is a Useful Indicator of HCQ Treatment Efficacy in SLE
Risa Wakiya¹, Hiromi Shimada¹, Kiyo Ueeda², Shusaku nakashima¹, Mikiya Kato¹, Taichi Miyagi¹, Yusuke Ushio³, Koichi Sugihara¹, Rina Mino³, mao mizusaki⁴, Kanako Chujo⁵, Tomohiro Kameda¹ and Hiroaki Dobashi⁶, ¹Kagawa University, Miki-cho, Kita-gun, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Kagawa university, Kagawa, Japan, ⁴Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Miki, Kita District, Kagawa, Japan, ⁶Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan
Background/Purpose: It is known that type 1 IFN and proinflammatory cytokines are associated with the pathogenesis of systemic lupus erythematosus (SLE). Recently, the S100 protein,…
Abstract Number: 1370 • ACR Convergence 2022
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
Gulnara Mamyrova¹, William Nguyen², Hassan Awal¹, Derek Jones¹, Alison Ehrlich³, Kathleen Brindle⁴, Shahriar Haji-Momenian⁴, Robert Sheets⁵, Adeline Y. Chin⁶, Shajia Lu⁷, Massimo Gadina⁷, Hanna Kim⁸, Olcay Y. Jones⁹, Lisa G Rider¹⁰ and Rodolfo V Curiel¹, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University, School of Medicine and Health Sciences, Washington, DC, ³Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Department of Radiology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of California San Diego, Rady Children's Hospital, San Diego, CA, ⁶Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁷Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁸Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Pediatric Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁰Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: This open-label 24-week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (JDM).Methods: Ten patients of…
Abstract Number: 1501 • ACR Convergence 2022
Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)
Isaac Cheng¹, Martin Li², Ho SO¹, Jack Lee², Chun Kwok Wong² and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Psoriatic Arthritis (PsA) is a complex, heterogeneous disease with chronic inflammation. Disease manifestations include the peripheral joint inflammation, dactylitis, enthesitis and skin psoriasis. Chronic…
Abstract Number: 1789 • ACR Convergence 2022
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Aakriti Arora¹, Lakshmi Jayaram², TEFERA ESHETU³ and FLORINA CONSTANTINESCU³, ¹MedStar Washington Hospital Center, Georgetown University, Washington, DC, ²McGaw Medical Center, Northwestern University, Chicago, IL, ³MedStar Washington Hospital Center, Washington, DC
Background/Purpose: Gout is one of the most common inflammatory joint diseases and is a disabling complication in patients with heart failure. Patients with gout and…
Abstract Number: 2088 • ACR Convergence 2022
Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort
Jacob N. Hunnicutt¹, Mary E. Georgiou², Anna Richards², Holly Quasny³, Laurence S Magder⁴, Daniel W. Goldman⁵ and Michelle Petri⁵, ¹GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, ²GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ³GlaxoSmithKline, Clinical Sciences, Research Triangle Park, NC, ⁴University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: The treatment target for systemic lupus erythematosus (SLE) is remission or, if this cannot be reached, the lowest disease activity achievable with the least…
Abstract Number: 0384 • ACR Convergence 2022
Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study
Jenny Lin Hong Shi¹, Steven H Lam², Ho So³, Edmund Li¹, Tena Li¹, Cheuk Chun Szeto¹ and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese university of Hong Kong, Hong Kong, Hong Kong, ³The Faculty of Medicine, CUHK, Hong Kong, Hong Kong
Background/Purpose: In the general population, hypertension (HT) is reported as one of the most important risk and modifiable factors to develop CVD. It is well…
Abstract Number: 0792 • ACR Convergence 2022
Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
Margaret Ma¹, Amelia Santosa¹, Kok Ooi Kong², Chuanhui Xu², Gim Gee Teng¹, Johnston GX Tang², Anselm Mak³, Frank Tay¹, Victoria WW Ng⁴, Joshua ZE Koh⁴, Warren Fong⁵, Li-Ching Chew⁶, Andrea Low⁷, annie law⁸, Yih Jia Poh⁸, Siaw Ing Yeo⁶, Ying Ying Leung⁹, Wei-Rui Goh⁶, Nur Emilia Roslan¹⁰, Tyng Yu Chuah¹⁰, Stanley Angkodjojo¹¹, Thaschawee Arkachaisri¹², Kai Liang Teh¹³, Kee Fong Phang¹⁴, Melonie Sriranganathan¹⁵, teck Choon Tan¹⁶, Peter Cheung¹ and Manjari Lahiri¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁴National University of Singapore, Singapore, Singapore, ⁵Singapore Health Services Pte Ltd (SHS), Singapore, Singapore, ⁶Singapore General Hospital, Singapore, Singapore, ⁷Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁸SingHealth, Singapore, Singapore, ⁹Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ¹⁰Sengkang General Hospital, Singapore, Singapore, ¹¹Sengkang General Hospital / Singhealth, Singapore, Singapore, ¹²KK Women's and Children's Hospital, SingHealth, Singapore, Singapore, ¹³KK Women's and Children's Hospital, Singapore, Singapore, ¹⁴Alexandra Hospital, Singapore, Singapore, ¹⁵Changi General Hospital, Singapore, Singapore, ¹⁶Khoo Teck Puat Hospital, Singapore, Singapore
Background/Purpose: Published data suggest no increased rate of flare of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination; however, the studies are limited by…
Abstract Number: 0993 • ACR Convergence 2022
SARS-CoV-2 Vaccine Side Effects and Infections in SLE
Laura Yan¹, Arielle Mendel², Evelyne Vinet², Fares Kalache³, Jennifer Lee¹, Popi Panaritis² and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Center, Montréal, QC, Canada
Background/Purpose: SLE patients are an especially vulnerable population in the face of the COVID pandemic due to their dysregulated endogenous immune system, further downregulated by…
Abstract Number: 1373 • ACR Convergence 2022
Increased Patient Contact May Mitigate Flares Among jSLE Patients
Jessica Fennell, Deanna Jannat-Khah, DrPH, MSPH and karen onel, Hospital for Special Surgery, New York, NY
Background/Purpose: Optimizing jSLE management is crucial to prevent flares as the damage sustained during flares contributes to lifelong morbidity and mortality. The onset of the…
Abstract Number: 1505 • ACR Convergence 2022
Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics
Nina Colla¹, Julia-Tatjana Maul², Burkhard Moeller³, Michael Nissen⁴, Nikhil Yawalkar⁵, Eleftherios Papagiannoulis⁶, Oliver Distler¹, Adrian Ciurea⁷ and Raphael Micheroli⁸, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Dermatology and Venereology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³Inselspital - University Hospital Bern, Bern, Switzerland, ⁴Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁵Department of Dermatology, University Hospital Inselspital Bern, Bern, Switzerland, ⁶Statistics Group, SCQM Foundation, Zurich, Switzerland., Zürich, ⁷University Hospital Zurich, Zürich, Switzerland, ⁸University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland
Background/Purpose: Biomechanical stress is a possible trigger of inflammation in psoriatic arthritis (PsA). The influence of physically demanding occupations on this potential association has not…
Abstract Number: 1806 • ACR Convergence 2022
Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing
Naomi Schlesinger¹, Lissa Padnick-Silver², Katie Obermeyer² and Brian LaMoreaux², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Acute gout flare often accompanies urate-lowering therapy initiation and is the most common adverse event associated with pegloticase, a recombinant pegylated uricase that rapidly…
Abstract Number: 2089 • ACR Convergence 2022
The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
Alicia Van¹, Vibeke Strand², Jiandong Su¹, Nicole Anderson¹, Cheryl F Rosen³, Sherief Marzouk⁴, Lee S Simon⁵ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²Stanford University School of Medicine, Stanford, CA, ³University of Toronto, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵SDG LLC, West Newton, MA
Background/Purpose: Skin involvement in Systemic Lupus Erythematosus (SLE) occurs in 50-85% of patients making it one of the most commonly affected organs in SLE. Previous…
Abstract Number: 0130 • ACR Convergence 2021
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S
Joseph Tkacz¹, Allison Perry¹, Helen Varker¹, Richard Bizier¹, Robert Ortmann² and Sandra Sze-jung Wu³, ¹IBM Watson Health, Bethesda, MD, ²AstraZeneca, Greenwood, IN, ³AstraZeneca, Wilmington, DE
Background/Purpose: Current literature characterizing the economic and clinical burden of systemic lupus erythematosus (SLE) is outdated and often does not consider SLE disease severity, which…
Abstract Number: 0376 • ACR Convergence 2021
Impact of Patient and Disease Characteristics on Global Functioning and Health in Patients with Axial Spondyloarthritis: A Bayesian Network Analysis of Data from an Early axSpA Cohort
Imke Redeker¹, Robert Landewé², Désirée van der Heijde³, Sofia Ramiro⁴, Annelies Boonen⁵, Maxime Dougados⁶, Juergen Braun⁷ and Uta Kiltz⁷, ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Current knowledge on the health status of patients (pts.) with axial spondyloarthritis (axSpA) mainly focusses on physical function and disease activity. Using a generic…
Abstract Number: 0796 • ACR Convergence 2021
Validation of the Simplified Disease Activity Index (SDAI) with a Quick Quantitative C-reactive Protein Assay (SDAI-Q) in Patients with Rheumatoid Arthritis: A National, Multicenter Study
Julia Schally¹, Henning Christian Brandt², Jan Brandt-Jrgens³, Gerd Burmester⁴, Hildrun Haibel⁵, Henriette Käding¹, Kirsten Karberg⁶, Susanne Lüders⁷, Burkhard Muche¹, Mikhail Protopopov⁴, Valeria Rios Rodriguez⁴, Murat Torgutalp⁴, Maryna Verba⁸, Silke Zinke⁹, Denis Poddubnyy¹⁰ and Fabian Proft⁴, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ²Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ³Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Praxis für Rheumatologie und Innere Medizin,, Berlin, Germany, ⁷Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁹Rheumapraxis Berlin, Berlin, Germany, ¹⁰Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Therapeutic decisions in RA patients should be based on regular disease activity assessment using scores like the Simplified Disease Activity Index (SDAI) or the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].